Dexcom, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $67.2M | 3,146 | 79.5% |
| Food and Beverage | $4.6M | 194,615 | 5.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3.7M | 1,461 | 4.3% |
| Consulting Fee | $2.6M | 155 | 3.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.4M | 821 | 2.8% |
| Current or prospective ownership or investment interest | $1.3M | 8 | 1.5% |
| Travel and Lodging | $1.1M | 2,361 | 1.3% |
| Honoraria | $1.1M | 531 | 1.3% |
| Grant | $628,639 | 2 | 0.7% |
| Education | $432.58 | 9 | 0.0% |
| Entertainment | $71.68 | 4 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM - (G7 PIVOTAL) | $6.5M | 0 | 101 |
| Evaluation of the Investigational Dexcom Continuous Monitoring (CGM) Sensor in Adult and Pediatric Subjects | $6.1M | 0 | 55 |
| MULTI-SESSION FEASIBILITY STUDY OF THE DEXCOM G7 DELTA CONTINUOUS GLUCOSE MONITORING (CGM) SENSOR IN ADULT AND PEDIATRIC SUBJECTS | $4.5M | 0 | 64 |
| EFFECTIVENESS AND SAFETY OF THE DEXCOM G6 CONTINUOUS GLUCOSE MONITORING SYSTEM IN NON-CRITICALLY ILL PATIENTS IN THE INPATIENT SETTING (HOSPITAL YSI) | $4.3M | 0 | 142 |
| EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINIOUS GLUCOSE MONITORING (CGM) SYSTEM (G7PIV#2) | $3.7M | 0 | 50 |
| COACH | $2.2M | 0 | 51 |
| G6 Pivotal | $2.2M | 0 | 12 |
| PREDIABETES AND TYPE 2 DIABETES DATA COLLECTION STUDY: T2 HELP (OBSERVATIONAL STUDY) | $1.7M | 0 | 86 |
| Multi-session evaluation of the Investigational Dexcom Continuous Glucose Monitoring (CGM) Sensor in Adult and Pediatric Participants | $1.6M | 0 | 8 |
| EVALUATION OF MODIFIED ADHESIVES WITH DEXCOM G7 SENSORS (BETA OH8) | $1.5M | 0 | 29 |
| POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | $1.4M | 0 | 239 |
| EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINIOUS GLUCOSE MONITORING (CGM) SYSTEM (OH7) | $1.2M | 0 | 12 |
| EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM GLUCOSE MONITORING (CGM) (G7 OUS) | $1.1M | 0 | 23 |
| MOBILE | $894,294 | 0 | 33 |
| EVALUATION OF THE PERFORMANCE AND DATA DELIVERY RELIABILITY OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM | $892,856 | 0 | 22 |
| TIME-IN-RANGE USING CGM MANAGEMENT OF GDM | $876,943 | 0 | 32 |
| EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM PROTOCOL | $859,159 | 0 | 36 |
| CONTINUOUS GLUCOSE MONITORING IN T2D BASAL INSULIN USERS (MOBILE) | $810,946 | 1 | 155 |
| EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM - (ALGO OUS G7) | $804,598 | 0 | 33 |
| EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM (BETA OH5) | $742,230 | 0 | 14 |
| FEASIBILITY STUDY OF THE DEXCOM G7 CONTINUOUS GLUCOSE MONITORING (CGM) DELTA SENSOR (DELTA OH3) | $713,928 | 0 | 11 |
| COMMUNITY GLUCOSE MONITORING PROJECT | $701,368 | 1 | 12 |
| Implementation of real-time continuous glucose monitoring in the hospital setting | $685,382 | 0 | 8 |
| Continuous Glucose Monitoring for Screening for Diabetes in Pregnancy: A comparative effectiveness randomized control trial | $679,382 | 0 | 8 |
| PERFORMANCE OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEMS IN PREGNANT WOMEN WITH DIABETES MELLITUS (G6G7PREG) | $660,614 | 0 | 41 |
| EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM | $643,814 | 0 | 15 |
| EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM (BETA OH6) | $620,170 | 0 | 13 |
| FEASIBILITY STUDY OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM (DEXTHANE) | $593,964 | 0 | 9 |
| FEASIBILITY STUDY EVALUATING THE PERFORMANCE OF MODIFIED DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM IN ADULTS WITH DIABETES MELLITUS | $580,086 | 0 | 14 |
| APAP Piv | $523,745 | 0 | 8 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Eric Topol, M.d, M.D | Cardiovascular Disease | La Jolla, CA | $2.8M | $0 |
| Jay Skyler, Md, MD | Internal Medicine | Miami, FL | $2.5M | $0 |
| Anita Swamy, M.d, M.D | Pediatric Endocrinology | Chicago, IL | $406,252 | $0 |
| Nicholas Argento, M.d.l, M.D.L | Endocrinology, Diabetes & Metabolism | Laurel, MD | $390,529 | $0 |
| Dr. Peter Attia, M.d, M.D | Surgery | San Diego, CA | $300,162 | $0 |
| Dr. Timothy Gilbert, M.d, M.D | Endocrinology, Diabetes & Metabolism | Baton Rouge, LA | $234,726 | $0 |
| Dr. Thomas Grace, M.d, M.D | Family Medicine | Findlay, OH | $233,520 | $0 |
| Dr. Daniel Katselnik, Md, MD | Endocrinology, Diabetes & Metabolism | Shavano Park, TX | $197,853 | $0 |
| Pablo Mora, Md, MD | Internal Medicine | Plano, TX | $175,308 | $0 |
| Dr. Martin Sarkar, D.o, D.O | Endocrinology, Diabetes & Metabolism | Frederick, MD | $162,013 | $0 |
| Dr. Egils Bogdanovics, M.d, M.D | Endocrinology, Diabetes & Metabolism | Torrington, CT | $157,503 | $0 |
| Davida Kruger, Msn,Aprn-Bc,Bc-Amd, MSN,APRN-BC,BC-AMD | Registered Nurse | Detroit, MI | $147,533 | $0 |
| Arelis Madera, Md, MD | Endocrinology, Diabetes & Metabolism | Port Charlotte, FL | $127,072 | $0 |
| Dr. Gregg Gerety, M.d, M.D | Endocrinology, Diabetes & Metabolism | Albany, NY | $126,396 | $0 |
| Mr. Bryan Urquhart, Pa-C, PA-C | Medical | Fredericksburg, VA | $117,717 | $0 |
| Dr. Grazia Aleppo, Md, MD | Endocrinology, Diabetes & Metabolism | Chicago, IL | $114,316 | $0 |
| Dr. Daniel Desalvo, Md, MD | Pediatric Endocrinology | Houston, TX | $95,234 | $0 |
| Catherine Kilpatrick, M.d, M.D | Internal Medicine | Fayetteville, AR | $93,883 | $0 |
| Dr. Aaron King, M.d, M.D | Family Medicine | San Antonio, TX | $92,157 | $0 |
| Helen Baron, M.d, M.D | Endocrinology, Diabetes & Metabolism | Rancho Mirage, CA | $86,618 | $0 |
| Dr. David Kayne, M.d, M.D | Specialist | Encino, CA | $78,673 | $0 |
| Dr. Jason Baker, M.d, M.D | Endocrinology, Diabetes & Metabolism | New York, NY | $77,624 | $0 |
| Dr. Karen Earle, Md, MD | Internal Medicine | San Francisco, CA | $73,214 | $0 |
| Dr. Wendy Lane, Md, MD | Endocrinology, Diabetes & Metabolism | Asheville, NC | $71,231 | $0 |
| Ernest Asamoah, Md, MD | Endocrinology, Diabetes & Metabolism | Indianapolis, IN | $71,118 | $0 |
Top Products
- Dexcom G6 Transmitter $11.6M
- DEXCOM G7 GSS (161) $6.6M
Associated Products (11)
- Dexcom G6 Transmitter $11.6M
- DEXCOM G7 GSS (161) $6.6M
- DEXCOM G6 TRANSMITTER $6.5M
- DEXCOM G6 CGM SYSTEM $3.6M
- Dexcom G5 Mobile CGM System $3.2M
- Dexcom CGM $1.8M
- Dexcom G6 CGM System $1.7M
- DEXCOM CGM $843,186
- Dexcom G4 Platinum $311,071
- DEXCOM G5 MOBILE $158,718
- DEXCOM STELO GLUCOSE BIOSENSOR $29,899
Payment Categories
- Food & Beverage $4.6M
- Consulting $2.6M
- Travel & Lodging $1.1M
- Research $67.2M
About Dexcom, Inc.
Dexcom, Inc. has made $84.5M in payments to 55,666 healthcare providers, recorded across 203,113 transactions in the CMS Open Payments database. In 2024, the company paid $19.3M. The top product by payment volume is Dexcom G6 Transmitter ($11.6M).
Payments were distributed across 260 medical specialties. The top specialty by payment amount is Endocrinology, Diabetes & Metabolism ($4.8M to 3,273 doctors).
Payment categories include: Food & Beverage ($4.6M), Consulting ($2.6M), Research ($67.2M), Travel & Lodging ($1.1M).
Dexcom, Inc. is associated with 11 products in the CMS Open Payments database, including Dexcom G6 Transmitter, DEXCOM G7 GSS (161), and DEXCOM G6 TRANSMITTER.